Germany has developed a new anti-skin cancer drug, which can destroy tumor cells in only 1-2 hours with little side effects and no scars. (Photo/Excerpted from the British Daily Mail) According to the British Daily Mail, Italian researchers working for ITM Technology in Germany recently conducted human experiments on 700 subjects in Italy. First, he put a rare radioactive isotope "Re-188" into the medicine and smeared it on the skin infected by tumor cells through surgical foil. 1-2 hours later, the foil was removed, and it was found that as many as 85% of the patients' tumor cells almost disappeared completely.
This therapy is mainly aimed at basal cell carcinoma and squamous cell carcinoma, which are relatively mild skin cancers. Others, such as radiotherapy and tumor "freezing", are often used to destroy early cancer cells.
If the disease has deteriorated into malignant melanoma, or the tumor is too deep, or grows in sensitive parts such as eyes, ears and nose, the patient must receive radiotherapy to cure it, but the disadvantage is that the whole course of treatment is quite time-consuming and has many side effects, which is a kind of torture to the patient's physiology and psychology.
Oliver barker, CEO of ITM Technology, said: "The biggest advantage of this therapy is that it can effectively and intensively destroy tumor cells without damaging the tissues around the wound, which can not only minimize the side effects, but also * * * the proliferation of skin cells, so that patients will not leave scars after being cured, which is different from traditional invasive surgery. After the success of the first round of experiments, we have actively participated in the second round of experiments in Germany and Australia. 」
According to statistics, there are as many as 654.38 million people suffering from skin cancer in Britain every year. The main reason is that many people do not take proper sun protection measures, so that the skin is directly exposed to ultraviolet rays, leading to skin cell lesions. If the second round of human trials can be carried out smoothly, the drug and its supporting course of treatment will be listed in the UK within two years.
Get healthy and high! ""fan group!